These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20043031)

  • 81. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O; Zhou Y
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [TBL] [Abstract][Full Text] [Related]  

  • 82. 2023 in review: FDA approvals of new medicines.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2024 May; 29(5):103966. PubMed ID: 38552777
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H; Matsumaru N; Tsukamoto K
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The year's new drugs & biologics, 2017, part II - News that shaped the industry in 2017.
    Graul AI; Dulsat C; Pina P; Tracy M; D'Souza P
    Drugs Today (Barc); 2018 Feb; 54(2):137-167. PubMed ID: 29637939
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 86. Pathway for approval of a gene therapy orphan product: treading new ground.
    Byrne BJ
    Mol Ther; 2013 Aug; 21(8):1465-6. PubMed ID: 23903569
    [No Abstract]   [Full Text] [Related]  

  • 87. US incentive scheme for neglected diseases: a good idea gone wrong?
    Doshi P
    BMJ; 2014 Jul; 349():g4665. PubMed ID: 25099712
    [No Abstract]   [Full Text] [Related]  

  • 88. Orphan drugs and orphan diseases. Round table proceedings, 3rd European Pediatric Neurology Society Congress. Nice, November 1999.
    Campos-Castelló J; Ponsot G; Feillet F; Vidailhet M; Maire I
    Eur J Paediatr Neurol; 2000; 4(3):141-9. PubMed ID: 10872111
    [No Abstract]   [Full Text] [Related]  

  • 89. Incentives for drug development--the curious case of colchicine.
    Kesselheim AS; Solomon DH
    N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
    [No Abstract]   [Full Text] [Related]  

  • 90. Duel over discounts. Pharma, providers at odds over 'orphan drugs'.
    Daly R
    Mod Healthc; 2012 Jan; 42(4):30-1. PubMed ID: 22359763
    [No Abstract]   [Full Text] [Related]  

  • 91. Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.
    Harada K; Toriyabe K; Ono S
    J Clin Pharmacol; 2020 Jan; 60(1):117-124. PubMed ID: 31364772
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 93. Drugs bill to rein in profits.
    Gershon D
    Nature; 1994 Mar; 368(6470):381. PubMed ID: 8133874
    [No Abstract]   [Full Text] [Related]  

  • 94. Adoption agent.
    Peota C
    Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583
    [No Abstract]   [Full Text] [Related]  

  • 95. The economics of priority review vouchers.
    Dimitri N
    Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Birgitte Volck.
    Nat Rev Drug Discov; 2017 May; 16(6):378-379. PubMed ID: 28559559
    [No Abstract]   [Full Text] [Related]  

  • 97. The Orphan Drug Act. Should it be changed?
    Sanders CA
    Arch Intern Med; 1993 Dec; 153(23):2623-5. PubMed ID: 8250658
    [No Abstract]   [Full Text] [Related]  

  • 98. Promoting the development of drugs against rare diseases: what more should be done?
    Westermark K; Llinares J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396
    [No Abstract]   [Full Text] [Related]  

  • 99. Orphan drug product regulation--United States.
    Haffner ME
    Int J Clin Pharmacol Ther; 2002 Feb; 40(2):84-8. PubMed ID: 11862977
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The Commercial Market For Priority Review Vouchers.
    Ridley DB; Régnier SA
    Health Aff (Millwood); 2016 May; 35(5):776-83. PubMed ID: 27140982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.